We are live on ! Find out more
KRRO icon

Korro Bio

82 hedge funds and large institutions have $95M invested in Korro Bio in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

264% more call options, than puts

Call options by funds: $579K | Put options by funds: $159K

0.06% less ownership

Funds ownership: 1.09%1.02% (-0.06%)

7% less funds holding

Funds holding: 8882 (-6)

24% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 25

30% less capital invested

Capital invested by funds: $135M → $95M (-$39.8M)

48% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 33

Holders
82
Holders Change
-6
Holders Change %
-6.82%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
17
Reduced
33
Closed
25
Calls
$579K
Puts
$159K
Net Calls
+$420K
Net Calls Change
+$86K

KRRO Hedge Fund Activity: Q4 2021 in Review

82 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q4 2021, worth a combined $95M — down 30% from $135M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of KRRO and 19 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 17 added.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.93M. The largest seller was Morgan Stanley, cutting an estimated $2M.

  • 82 institutional investors held Korro Bio (KRRO) as of Q4 2021, down from 88 in Q3 2021.
  • Funds reported $95M of Korro Bio stock for Q4 2021, down 30% quarter-over-quarter.
  • 19 funds opened new Korro Bio positions in Q4 2021 and 25 closed out, a net change of -6 holders.
  • The largest Korro Bio buyer in Q4 2021 was Jacobs Levy Equity Management, an estimated $1.93M added.
  • The largest Korro Bio seller in Q4 2021 was Morgan Stanley, an estimated $2M sold.

Based on aggregated 13F filings for Q4 2021.